International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories

Essentials AFSTYLA exhibits ≈50% underestimation in activity when the one‐stage (OS) assay is utilized. A field study compared the performance of AFSTYLA with Advate in factor VIII activity assays. AFSTYLA activity can be monitored with both the chromogenic substrate and the OS assay. The consistent OS underestimation allows for a conversion factor to be applied to OS results.

[1]  P. Turecek,et al.  A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  E. Santagostino,et al.  Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. , 2016, Blood.

[3]  J. Oldenburg,et al.  A critical appraisal of one‐stage and chromogenic assays of factor VIII activity , 2016, Journal of thrombosis and haemostasis : JTH.

[4]  Stefan Schmidbauer,et al.  Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. , 2015, Thrombosis research.

[5]  B. Konkle,et al.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  G. Lippi,et al.  Problems and Solutions in Laboratory Testing for Hemophilia , 2013, Seminars in Thrombosis & Hemostasis.

[7]  T. Weimer,et al.  Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. , 2013, Thrombosis research.

[8]  D. Viuff,et al.  International comparative field study of N8 evaluating factor VIII assay performance , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  J. Ingerslev,et al.  Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one‐stage clotting assays , 2004, Journal of thrombosis and haemostasis : JTH.

[10]  T. Barrowcliffe,et al.  Coagulation and Chromogenic Assays of Factor VIII Activity: General Aspects, Standardization, and Recommendations , 2002, Seminars in thrombosis and hemostasis.

[11]  M. Mikaelsson,et al.  Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. , 2002, Seminars in thrombosis and hemostasis.